Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 bln (updated)

Alpine Immune Sciences

10/04/2024 21:16

(Adds share movement in paragraph 4 and details throughout)
       April 10 (Reuters) - Vertex Pharmaceuticals  VRTX.O 
will acquire therapy developer Alpine Immune Sciences  ALPN.O 
for $65 per share, or about $4.9 billion in cash, the companies
said on Wednesday.
    With the acquisition, Vertex will add Alpine's portfolio of
protein-based immunotherapies to treat autoimmune and
inflammatory diseases.
    The transaction, approved by Vertex and Alpine's boards, is
expected to close in the second quarter of 2024.
    Shares of Alpine were up 20% in extended trading.

 (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi
Majumdar)
 ((Christy.Santhosh@thomsonreuters.com))